Ipamorelin vs Mazdutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both Ipamorelin and Mazdutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Ipamorelin Mazdutide
Weight 711.85 Da 4,563.1 Da
Half-life ~2 hours 6-8 days
Chain 5 amino acids 33 amino acids
Type Growth hormone secretagogue Oxyntomodulin analog with fatty acid conjugation
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Research Evidence
Ipamorelin Mazdutide
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest October 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.